Get the Daily Brief
Latest Biotech News
Bird‑flu spillovers spur renewed phage‑therapy research
Widespread H5N1 outbreaks and occasional human spillovers have renewed interest in bacteriophage approaches for secondary bacterial infections and as vaccine platforms. Public health trackers...
$230 billion at risk: Top blockbusters face 2026‑29 patent cliff
GEN’s analysis identified roughly $230 billion in annual sales tied to drugs whose key U.S. patents expire between 2026 and 2029; the top 20 alone generated about $176 billion last year. The...
Thermo Fisher buys Clario: $9 billion bet on trial data software
Thermo Fisher Scientific agreed to acquire Clario for about $9 billion, moving to integrate Clario’s clinical-trial software that captures, manages and analyzes endpoint data with Thermo Fisher’s...
Pfizer sues Metsera and Novo Nordisk... takeover fight turns legal
Pfizer filed suit in Delaware against Metsera’s board and Novo Nordisk after Novo launched a counterproposal for obesity developer Metsera, seeking to block Metsera from terminating an earlier...
Moderna’s retrenchment... Covid windfall fails to translate to wider pipeline
Moderna’s post‑pandemic strategy has faltered as Covid vaccine revenues decline and promised mRNA pipeline successes have yet to materialize, according to an expansive industry account. The...
Bird‑flu surge spurs phage therapy research: CDC and industry respond
Rising HPAI (H5N1) spillovers and mounting agricultural losses have renewed interest in bacteriophage therapies, researchers and public‑health agencies report. The U.S. CDC and USDA briefings show...
Top 20 drugs hit patent cliff: $176.4 billion at risk through 2029
An analysis identified the top 20 blockbuster drugs facing key U.S. patent expirations between 2026 and 2029, representing roughly $176.4 billion in annual sales. The report links looming...
Thermo’s Orbitrap Astral Zoom MS... mass spec scales multiomics
Thermo Fisher rolled out the Orbitrap Astral Zoom mass spectrometer to boost throughput and sensitivity for proteomics and metabolomics studies, aiming to scale multiomics in clinical and...
AI models and Boltz‑2 reshape binding‑affinity prediction for discovery
New large quantitative models are changing structure‑based small‑molecule discovery: MIT and Recursion’s Boltz‑2 demonstrated rapid, accurate binding‑affinity predictions, while companies like...
Health Canada to reclassify cloned‑animal products: silent policy shift
Health Canada plans to remove foods derived from cloned cattle and swine from its "novel foods" list, a policy change that would end mandatory pre‑market safety reviews and public disclosure for...
Human kidney organoids scaled for porcine transplant research
Researchers reported a systematic process to produce human kidney organoids intended to advance porcine‑based xenotransplantation and regenerative‑medicine studies, publishing methods that aim to...
Turbocharged Cas9 nuclear entry: internal NLS insertions boost editing
Researchers at UC Berkeley’s Innovative Genomics Institute reported a protein‑engineering strategy that inserts multiple nuclear localization signals into internal loops of Cas9 to increase...
Pfizer Sues to Block Novo Bid—Metsera Deal in Limbo
Pfizer filed suit in Delaware to enforce its September acquisition agreement with obesity biotech Metsera and to block Novo Nordisk’s competing proposal. Pfizer alleges Metsera’s board and Novo...
FDA Halts Intellia's CRISPR Trials After Liver Complications
The FDA placed a clinical hold on Intellia’s two Phase 3 studies of nexiguran ziclumeran (nex‑z), a CRISPR‑based therapy for transthyretin amyloidosis, following liver safety signals. The agency’s...
Gene Therapy 'Cure' for ADA‑SCID: 95% Success in Multi‑Year Follow‑Up
A joint UCL–UCLA team reported multi‑year follow‑up showing approximately 95% success and no serious safety signals for UCL/A‑ADA gene therapy in children with ADA‑SCID, according to a New England...
Human Kidney Organoids Scaled—Porcine Transplant Demonstrates Feasibility
Researchers published a Nature Biomedical Engineering study describing a reproducible method to produce thousands of human kidney organoids and the first experiments integrating those organoids...
Moderna Faces Downturn—Restructuring as Covid Windfall Erodes
A detailed review of Moderna’s trajectory documents major commercial and strategic challenges since its Covid vaccine peak: revenue declines for its pandemic shot, layoffs, restructurings and...
Bird flu spillovers revive phage therapy and vaccine research
Rising HPAI (H5N1) spillovers into livestock and occasional human cases have renewed interest in bacteriophage therapeutics and phage‑based vaccine platforms. A review citing CDC and USDA figures...
FDA Commissioner Signals New Deregulatory Moves—Industry Watches
FDA Commissioner Marty Makary publicly signaled forthcoming “deregulatory” actions, expanding on the agency’s recent relaxation of biosimilar trial requirements. Makary framed the steps as agency...
AI Models Close In on Binding Affinity—Boltz‑2 and Physics‑Grounded LQMs
Researchers from MIT and partners released Boltz‑2 and highlighted the rise of physics‑grounded large quantitative models (LQMs) for drug discovery. Boltz‑2 led binding‑affinity prediction at...